Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.75 |
| ▸ | HTR2C | P28335 | 5/20 | 0.48 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.39 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.39 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.39 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.39 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.39 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.39 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.39 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.39 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | HTR2B | P41595 | 4/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2263979 | 0.98 | PNMT (0.72) | PNMTHTR2CADCY6ADCY3ADCY9 | |
| Hydrochloric Acid SCHEMBL11181806 | 0.98 | PNMT (0.72) | PNMTHTR2CADCY6ADCY3ADCY9 | |
| SCHEMBL13441 | 0.86 | — | — | |
| SCHEMBL11088 | 0.84 | — | — | |
| Bromide SCHEMBL28557676 | 0.84 | PNMT (0.95) | PNMTCD44MAOBDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL366688 | 0.84 | PNMT (0.95) | PNMTCD44MAOBDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL1427992 | 0.82 | PNMT (0.69) | PNMTHTR2CCD44MAOB | |
| Iodide SCHEMBL30536887 | 0.82 | PNMT (0.69) | PNMTHTR2CCD44MAOB | |
| Hydrochloric Acid SCHEMBL5317536 | 0.82 | PNMT (0.91) | PNMTCD44MAOB | |
| SCHEMBL562638 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778243-A2 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | claimed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | claimed |
| WO-2006004931-A2 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-01-05 | — | — | US | claimed |
| EP-0555824-A1 | N-alpha-arylsulfonylated benzimidazolylalaninamide derivatives, medicaments based thereon and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-18 | — | — | EP | claimed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| EP-3248968-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-11-29 | — | — | EP | disclosed |
| EP-3248968-A1 | RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-11-29 | — | — | EP | disclosed |
| US-20020045635-A1 | Novel mGluR antagonists and a method for their synthesis | HOFFMANN-LA ROCHE, INC. | 2002-04-18 | — | — | US | disclosed |
| US-6369222-B1 | NITRO- AND CYANO-1,2,4,5-TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES; BRAIN, EYE, MUSCULAR, PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2002006288-A1 | TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| US-5391556-A | Thrombin inhibitors | KARL THOMAE GMBH (DE) | 1995-02-21 | — | — | US | disclosed |
| EP-0555824-A1 | N-alpha-arylsulfonylated benzimidazolylalaninamide derivatives, medicaments based thereon and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-18 | — | — | EP | disclosed |
| US-4414225-A | Azepine derivatives and their anti-thrombotic compositions and methods | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-11-08 | — | — | US | disclosed |
| EP-0058341-A1 | Azepine derivatives, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1982-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | HTR5A, HTR4, HTR7 | PNMT 89/4885HTR2C 5/4885ADCY6 1082/4885 |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | PNMT 3068/4885HTR2C 1971/4885ADCY6 820/4885 |
| US-20020045635-A1 | Novel mGluR antagonists and a method for their synthesis | GRM1, GRM5, GRM2 | PNMT 308/4885HTR2C 76/4885ADCY6 618/4885 |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | PNMT 4190/4885HTR2C 3745/4885ADCY6 4376/4885 |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | PNMT 4190/4885HTR2C 3745/4885ADCY6 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.